Osteoporosis



Immediate Effect Of Whole-Body Vibration And Walk in Osteoporosis/Osteopenia


Condition:   Osteoporosis
Interventions:   Other: Training in the vibrating platform;   Other: Walk
Sponsor:   Universidade Federal de Pernambuco
Not yet recruiting


A Comparison of Subject-administered Romosozumab With Healthcare Provider-administered Romosozumab for Osteoporosis


Condition:   Post-Menopausal Osteoporosis
Interventions:   Drug: HCP administration with PFS;   Device: Subject self-administration with AI/Pen
Sponsor:   Amgen
Recruiting


Jogging in the Change of Osteoporosis


Condition:   Osteoporosis
Intervention:   Behavioral: jogging
Sponsors:   Peking University People's Hospital;   Shenzhen Sun Yat-sen Cardiovascular Hospital;   Wujin People's Hospital;   Chongqing Zhongshan Hospital
Not yet recruiting


Dental Panoramic Radiographs to Screen for Post-menopausal Osteoporosis


Condition:   Osteoporosis, Postmenopausal
Interventions:   Diagnostic Test: Dental panoramic radiograph;   Diagnostic Test: DXA
Sponsors:   University of Parma;   Queen Mary University of London
Not yet recruiting


Efficacy of Oral Ibandronate in Osteoporosis


Condition:   Osteoporosis
Interventions:   Drug: Ibandronate;   Drug: Oral Ibandronate and Vitamin D
Sponsor:   Shinshu University
Recruiting


Efficacy of Zoledronic Acid in Osteoporosis


Condition:   Osteoporosis
Interventions:   Drug: "Zoledronic acid", "Reclast®";   Drug: "Zoledronic acid", "Reclast®" and "active vitamin D", "alfacalcidol®"
Sponsor:   Shinshu University
Recruiting


Treatment With Zoledronic Acid Subsequent to Denosumab in Osteoporosis


Condition:   Osteoporosis
Intervention:   Drug: Zoledronic Acid
Sponsors:   Aarhus University Hospital;   University of Aarhus;   Amgen
Active, not recruiting


A Comparison of PF708 and Forteo in Osteoporosis Patients


Condition:   Osteoporosis
Interventions:   Drug: Teriparatide (PF708);   Drug: Teriparatide (Forteo)
Sponsor:   Pfenex, Inc
Active, not recruiting


Multicenter Cohort Study on Osteoporosis


Condition:   Osteoporosis
Intervention:  
Sponsors:   Shanghai University of Traditional Chinese Medicine;   Wangjing Hospital, China Academy of Chinese Medical Sciences;   Dongzhimen Hospital, Beijing;   The 309th Hospital of Chinese People's Libertation Army;   The First Affiliated Hospital, Guangzhou University of TCM;   Guangdong Provincial Hospital of Traditional Chinese Medicine;   Affiliated Hospital of Changchun University of Chinese Medicine;   Gansu Provincial Hospital;   Luoyang Zhenggu Hospital;   Guangzhou Kingmed Diagnostics Co., Ltd.
Recruiting


A Safety and Efficacy Study to Evaluate AMG 785 in South Korean Women With Osteoporosis.


Condition:   Postmenopausal Osteoporosis
Interventions:   Drug: Romosozumab;   Drug: Placebo
Sponsor:   Amgen
Active, not recruiting


Denosumab for the Treatment of Osteoporosis in Children: A Pilot Study


Condition:   Osteoporosis
Interventions:   Drug: Zoledronic Acid;   Drug: Denosumab
Sponsor:   Children's Hospital of Eastern Ontario
Recruiting


Shock Wave Therapy for Osteoporosis


Condition:   Osteoporosis
Intervention:   Device: Unfocused extracoporeal shock wave therapy
Sponsor:   UMC Utrecht
Completed


PTH and Vibration in OSteoporosis Study


Condition:   Osteoporosis
Interventions:   Other: whole-body vibration;   Drug: teriparatide
Sponsors:   Odense University Hospital;   University of Southern Denmark;   Copenhagen University Hospital, Denmark;   Hospital of South West Denmark;   Sygehus Lillebaelt;   OPEN - Odense Patient data Explorative Network;   Region of Southern Denmark
Active, not recruiting


The Effect of Theory Menu-Based Intervention on Vitamin D Adherence in People With Osteoporosis-Pilot Study


Condition:   Osteoporosis
Interventions:   Behavioral: HAPA menu-based mini-video;   Behavioral: Standard care
Sponsor:   McMaster University
Completed


Characteristics and Management of Postmenopausal Women With Osteoporosis Treated With Prolia® in France


Condition:   Post Menopausal Osteoporosis
Intervention:   Drug: AMG 162 - Prolia
Sponsor:   Amgen
Active, not recruiting


A Double-blind Study to Compare the Safety and Efficacy of Romosozumab (AMG 785) Versus Placebo in Men With Osteoporosis


Condition:   Osteoporosis in Men
Interventions:   Drug: AMG 785;   Drug: Placebo
Sponsor:   Amgen
Completed


The Treatment of Osteoporosis Using a Combination of Teriparatide (Forteo) and Denosumab


Condition:   Osteoporosis
Interventions:   Drug: Standard Clinical Practice Regimen;   Drug: Experimental Cyclic Regimen
Sponsor:   Health Research, Inc.
Active, not recruiting


A Randomized Phase 3 Study to Evaluate Two Formulations of Romosozumab in Postmenopausal Women With Osteoporosis


Condition:   Postmenopausal Osteoporosis
Interventions:   Drug: Romosozumab 90 mg/mL;   Drug: Placebo 90 mg/mL;   Drug: Romosozumab 70 mg/mL;   Drug: Placebo 70 mg/mL
Sponsor:   Amgen
Completed


Point-of-care Osteoporosis Diagnostics With Bindex® Pocket Size Instrument and FRAX


Condition:   Osteoporosis
Intervention:  
Sponsors:   Bone Index Finland Ltd;   Merck Sharp & Dohme Corp.
Completed


Efficacy, Safety and Tolerability of Romosozumab in the Treatment of Japanese Women With Postmenopausal Osteoporosis


Condition:   Postmenopausal Osteoporosis (PMO)
Interventions:   Drug: Romosozumab;   Drug: Placebo
Sponsor:   Amgen
Completed


Oklahoma Native American Women's Osteoporosis Screening Study


Condition:   Osteoporosis
Intervention:  
Sponsor:   Oklahoma State University
Active, not recruiting


Bindex Ultrasonometer for Osteoporosis Diagnostics


Condition:   Osteoporosis
Intervention:  
Sponsors:   Bone Index Finland Ltd;   HealthEast Care System
Terminated


Efficacy and Safety of Romosozumab Treatment in Postmenopausal Women With Osteoporosis


Condition:   Postmenopausal Osteoporosis
Interventions:   Drug: Romosozumab;   Drug: Placebo;   Drug: Denosumab
Sponsor:   Amgen
Completed


Phase 2 Dose-finding Study to Evaluate the Effects of BA058 in the Treatment of Postmenopausal Women With Osteoporosis


Condition:   Osteoporosis
Interventions:   Drug: teriparatide;   Drug: Placebo;   Drug: BA058 20 µg;   Drug: BA058 40 µg;   Drug: BA058 80 µg
Sponsor:   Radius Health, Inc.
Completed


A Study to Evaluate Denosumab in the Treatment of Postmenopausal Osteoporosis


Condition:   Osteoporosis
Interventions:   Drug: placebo;   Drug: Denosumab
Sponsor:   Amgen
Completed

Refine Your Search Advanced Search